Duncker Streett & Co. Inc. Has $2.87 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Duncker Streett & Co. Inc. trimmed its position in Bristol-Myers Squibb (NYSE:BMY) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,002 shares of the biopharmaceutical company’s stock after selling 1,999 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $2,873,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Riversedge Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 3.2% during the 3rd quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 178 shares during the last quarter. Vicus Capital lifted its position in shares of Bristol-Myers Squibb by 3.9% during the 3rd quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 179 shares during the last quarter. Cassia Capital Partners LLC lifted its position in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Cassia Capital Partners LLC now owns 7,931 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 182 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 182 shares during the last quarter. Finally, Front Row Advisors LLC grew its stake in Bristol-Myers Squibb by 17.5% in the fourth quarter. Front Row Advisors LLC now owns 1,222 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 182 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Wells Fargo & Company dropped their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $61.12.

Bristol-Myers Squibb Stock Down 0.5 %

Shares of BMY stock traded down $0.25 during midday trading on Wednesday, reaching $48.26. 11,931,277 shares of the stock were exchanged, compared to its average volume of 10,940,481. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The company’s 50 day moving average is $51.27 and its two-hundred day moving average is $51.62. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The firm has a market cap of $97.81 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the business posted $1.82 EPS. The firm’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.97%. Bristol-Myers Squibb’s payout ratio is 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.